HK Stock Market Move | CARSGEN-B (02171) rises over 5%; CT1190B and CT071 research data to be presented at the 2026 ASH Annual Meeting

CARSGEN-B (02171) rose over 5%, up 5.05% as of press time at HK$11.43, with turnover of HK$7.373 million. On the news front, CARSGEN-B announced that the abstract of research results for CT1190B (a universal CAR-T candidate targeting CD19/CD20) in the treatment of relapsed/refractory large B-cell lymphoma, and the abstract of research results for CT071 (an autologous CAR-T candidate targeting GPRC5D) in the treatment of relapsed/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM), have been published at the 68th American Society of Hematology (ASH) Annual Meeting. The announcement stated that research data for the two candidate products will be presented in poster form at the ASH Annual Meeting. Updated data from the study of CT0596 (a universal CAR-T candidate targeting BCMA) in the treatment of R/R MM and primary plasma cell leukemia will be published in a separate company announcement in December 2026.